Monitoring eGFR in Severe Kidney Impairment

Monitoring Schedule Based on CKD Stage

For patients with eGFR 25 mL/min/1.73 m² (CKD stage 4), laboratory evaluations including eGFR should be performed every 3-5 months 1, 2
More frequent monitoring (every 1-3 months) is recommended if there are changes in medications that affect kidney function, signs of disease progression, or if the patient is approaching CKD stage 5 (eGFR <15 mL/min/1.73 m²) 1, 2

Recent initiation or dose adjustment of medications that affect kidney function (ACE inhibitors, ARBs, SGLT2 inhibitors) 3, 4
Signs of volume overload or depletion 1
Electrolyte abnormalities, particularly hyperkalemia 5
Acute illness or exposure to nephrotoxins 3

Along with eGFR, monitor serum electrolytes, particularly potassium and calcium 1, 2
Assess for metabolic acidosis with serum electrolytes 1
Check hemoglobin for anemia, which commonly occurs with CKD stage 4 1
Evaluate for metabolic bone disease with serum calcium, phosphate, PTH, and vitamin 25(OH)D 1, 2
Monitor albuminuria to assess disease progression and response to therapy 3

If the patient is on medications requiring dose adjustments based on kidney function (such as metformin or certain aldosterone antagonists), more frequent monitoring may be needed 6
For patients with diabetes and CKD, monitoring should include both eGFR and albuminuria at least annually, with more frequent monitoring for those at higher risk of progression 3
If the patient has recently started SGLT2 inhibitors, be aware that there may be an initial, reversible decrease in eGFR that is generally not an indication to discontinue therapy 4

Don't confuse small elevations in serum creatinine (up to 30%) with ACE inhibitors or ARBs with acute kidney injury 2
Remember that certain medications may need to be held during acute illness to prevent further kidney injury 3